{"id":63662,"date":"2026-06-24T07:08:14","date_gmt":"2026-06-24T11:08:14","guid":{"rendered":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/merck-secures-eu-approval-for-bladder-cancer-combo-israel-defiant-on-lebanon-withdrawal\/63662\/"},"modified":"2026-06-24T07:08:14","modified_gmt":"2026-06-24T11:08:14","slug":"merck-secures-eu-approval-for-bladder-cancer-combo-israel-defiant-on-lebanon-withdrawal","status":"publish","type":"post","link":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/merck-secures-eu-approval-for-bladder-cancer-combo-israel-defiant-on-lebanon-withdrawal\/63662\/","title":{"rendered":"Merck Secures EU Approval for Bladder Cancer Combo; Israel Defiant on Lebanon Withdrawal"},"content":{"rendered":"<h2>Key Takeaways<\/h2>\n<ul>\n<li><strong>Merck (<a href=\"\/stock\/MRK\">MRK<\/a>)<\/strong> received <strong>European Commission (EC)<\/strong> approval for its <strong>Keytruda<\/strong> plus <strong>Padcev<\/strong> combination, reducing the risk of death by <strong>50%<\/strong> in certain bladder cancer patients.<\/li>\n<li><strong>Israel&#39;s Defense Minister<\/strong> declared the military will not withdraw from <strong>South Lebanon<\/strong>, even if the <strong>United States<\/strong> demands it, citing critical security needs.<\/li>\n<li>The <strong>Merck<\/strong> approval marks the first and only <strong>PD-1 inhibitor plus antibody-drug conjugate (ADC)<\/strong> regimen available for cisplatin-ineligible resectable bladder cancer in the EU.<\/li>\n<li>Geopolitical tensions escalated as <strong>Israel<\/strong> signaled a move toward &quot;military independence&quot; from the <strong>U.S.<\/strong> amid ongoing ceasefire negotiations in <strong>Switzerland<\/strong>.<\/li>\n<\/ul>\n<h2>Merck Bolsters Oncology Leadership with EU Approval<\/h2>\n<p>The <strong>European Commission<\/strong> has officially approved <strong>Merck (<a href=\"\/stock\/MRK\">MRK<\/a>)<\/strong>&#39;s anti-PD-1 therapy, <strong>Keytruda<\/strong>, in combination with <strong>Padcev<\/strong> (enfortumab vedotin-ejfv), for the treatment of adults with resectable muscle-invasive bladder cancer (MIBC). This specific approval targets patients who are ineligible for cisplatin-containing chemotherapy, addressing a significant unmet medical need in the region.<\/p>\n<p>The decision is backed by the pivotal <strong>Phase 3 KEYNOTE-905<\/strong> trial, which demonstrated that the perioperative regimen reduced the risk of death by <strong>50%<\/strong> and the risk of event-free survival (EFS) events by <strong>60%<\/strong> compared to surgery alone. <em>Analysts view this as a major victory for Merck&#39;s oncology franchise, further solidifying Keytruda&#39;s position as a cornerstone of modern cancer care.<\/em><\/p>\n<h2>Israel Rejects U.S. Pressure on Lebanon Buffer Zone<\/h2>\n<p>In a sharp break from diplomatic expectations, <strong>Israel&#39;s Defense Minister<\/strong> vowed that the <strong>Israel Defense Forces (IDF)<\/strong> will maintain their presence in the southern <strong>Lebanon<\/strong> security zone. The minister stated that <strong>Israel<\/strong> would defy even a direct demand from the <strong>United States<\/strong> to withdraw, emphasizing that the safety of northern Israeli communities is a non-negotiable &quot;red line.&quot;<\/p>\n<p>This defiance comes as the <strong>U.S.<\/strong> and <strong>Iran<\/strong> report &quot;encouraging progress&quot; in separate talks held in <strong>Switzerland<\/strong>. <em>Market participants are closely monitoring these developments, as the hardline stance from Jerusalem has already led to a decrease in the perceived probability of a permanent peace deal with Hezbollah.<\/em><\/p>\n<h2>Strategic Shifts in Defense and Healthcare<\/h2>\n<p>The dual developments highlight a period of significant transition in both the pharmaceutical and geopolitical landscapes. While <strong>Merck (<a href=\"\/stock\/MRK\">MRK<\/a>)<\/strong> expands its reach in the <strong>$40 billion<\/strong> global oncology market, <strong>Israel<\/strong> is signaling a desire to &quot;free itself&quot; from military dependence on the <strong>U.S.<\/strong> to build an independent armaments system.<\/p>\n<p>The <strong>EC<\/strong> approval for <strong>Keytruda<\/strong> covers all 27 <strong>EU<\/strong> member states plus <strong>Iceland<\/strong>, <strong>Liechtenstein<\/strong>, and <strong>Norway<\/strong>. Meanwhile, the ongoing hostilities in <strong>Lebanon<\/strong> continue to impact regional stability, with <strong>Israel<\/strong> insisting that its troops will remain in the buffer zone &quot;for as long as required&quot; to neutralize threats from <strong>Hezbollah<\/strong>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key Takeaways Merck (MRK) received European Commission (EC) approval for its Keytruda plus Padcev combination, reducing the risk of death [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":50383,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"rank_math_schema_Article":[],"rank_math_focus_keyword":[],"rank_math_description":[],"financial_data_references":[],"stock_symbols_mentioned":[],"footnotes":""},"categories":[5012],"tags":[13517,1067,14834,4824,14836,14837,5016,18538,5227,5249,5556,6854,8715,9332],"class_list":["post-63662","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-breaking-news","tag-adc","tag-mrk","tag-bladder-cancer","tag-geopolitics","tag-mibc","tag-efs","tag-israel","tag-us-israel-relations","tag-healthcare","tag-idf","tag-merck","tag-lebanon","tag-oncology","tag-ec"],"_links":{"self":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/63662","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/comments?post=63662"}],"version-history":[{"count":0,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/63662\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media\/50383"}],"wp:attachment":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media?parent=63662"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/categories?post=63662"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/tags?post=63662"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}